WO2006084141A8 - Suspension formulation of interferon - Google Patents

Suspension formulation of interferon

Info

Publication number
WO2006084141A8
WO2006084141A8 PCT/US2006/003861 US2006003861W WO2006084141A8 WO 2006084141 A8 WO2006084141 A8 WO 2006084141A8 US 2006003861 W US2006003861 W US 2006003861W WO 2006084141 A8 WO2006084141 A8 WO 2006084141A8
Authority
WO
WIPO (PCT)
Prior art keywords
interferon
suspension formulation
vehicle
formulation
suspension
Prior art date
Application number
PCT/US2006/003861
Other languages
French (fr)
Other versions
WO2006084141A2 (en
WO2006084141A3 (en
Inventor
Rupal A Ayer
Paula Dennis
Michael A Desjardin
Stanley Lam
Kui Liu
James E Matsuura
Latha Narayanan
Catherine Rohloff
Pauline C Zamora
Original Assignee
Alza Corp
Rupal A Ayer
Paula Dennis
Michael A Desjardin
Stanley Lam
Kui Liu
James E Matsuura
Latha Narayanan
Catherine Rohloff
Pauline C Zamora
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp, Rupal A Ayer, Paula Dennis, Michael A Desjardin, Stanley Lam, Kui Liu, James E Matsuura, Latha Narayanan, Catherine Rohloff, Pauline C Zamora filed Critical Alza Corp
Publication of WO2006084141A2 publication Critical patent/WO2006084141A2/en
Publication of WO2006084141A3 publication Critical patent/WO2006084141A3/en
Publication of WO2006084141A8 publication Critical patent/WO2006084141A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

A suspension formulation of interferon includes a non-aqueous, single-phase vehicle including at least one polymer and at least one solvent, the vehicle exhibiting viscous fluid characteristics, and an interferon contained in a particle formulation dispersed in the vehicle. The particle formulation includes a stabilizing component comprising one or more stabilizers selected from the group consisting of carbohydrates, antioxidants, and amino acids. The suspension formulation is characterized in that less than 10% of the interferon degrades over 3 months under an accelerated storage condition.
PCT/US2006/003861 2005-02-03 2006-02-03 Suspension formulation of interferon WO2006084141A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65022605P 2005-02-03 2005-02-03
US60/650,226 2005-02-03

Publications (3)

Publication Number Publication Date
WO2006084141A2 WO2006084141A2 (en) 2006-08-10
WO2006084141A3 WO2006084141A3 (en) 2006-09-21
WO2006084141A8 true WO2006084141A8 (en) 2006-11-09

Family

ID=36587040

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/003857 WO2006084139A2 (en) 2005-02-03 2006-02-03 An implantable interferon-containing device
PCT/US2006/003861 WO2006084141A2 (en) 2005-02-03 2006-02-03 Suspension formulation of interferon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2006/003857 WO2006084139A2 (en) 2005-02-03 2006-02-03 An implantable interferon-containing device

Country Status (5)

Country Link
US (2) US20060263433A1 (en)
EP (2) EP2361630A1 (en)
JP (1) JP2008528698A (en)
CA (1) CA2596966A1 (en)
WO (2) WO2006084139A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846072B2 (en) 2004-09-17 2014-09-30 Durect Corporation Controlled delivery system
US8956644B2 (en) 2006-11-03 2015-02-17 Durect Corporation Transdermal delivery systems

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
JP4865330B2 (en) 2002-12-13 2012-02-01 デュレクト コーポレーション Oral drug delivery system
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006083761A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP2008528698A (en) 2005-02-03 2008-07-31 インターシア セラピューティクス，インコーポレイティド Implantable interferon-containing devices
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
MX2008014870A (en) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator.
ES2422864T3 (en) * 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Osmotic release systems and piston units
US8814930B2 (en) * 2007-01-19 2014-08-26 Elixir Medical Corporation Biodegradable endoprosthesis and methods for their fabrication
US20130150943A1 (en) 2007-01-19 2013-06-13 Elixir Medical Corporation Biodegradable endoprostheses and methods for their fabrication
US20080177373A1 (en) 2007-01-19 2008-07-24 Elixir Medical Corporation Endoprosthesis structures having supporting features
WO2008133908A2 (en) * 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2009088414A2 (en) 2007-12-06 2009-07-16 Durect Corporation Oral pharmaceutical dosage forms
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US20100092566A1 (en) * 2008-10-15 2010-04-15 Alessi Thomas R Highly concentrated drug particles, formulations, suspensions and uses thereof
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010146536A1 (en) * 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
WO2011007327A2 (en) * 2009-07-16 2011-01-20 Koninklijke Philips Electronics N.V. Suspension for therapeutic use and device for delivering said suspension
WO2011037623A1 (en) * 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
ES2563737T3 (en) * 2011-05-20 2016-03-16 Ares Trading S.A. IFN-beta compositions, preparation methods and uses thereof
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DK2583677T1 (en) 2011-10-21 2015-01-19 Abbvie Inc Methods for treatment of HCV comprising at least two direct-acting antiviral agents ribavirin, interferon but not
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2012321101A1 (en) * 2011-11-23 2013-06-06 Durect Corporation Radiation-sterilized biodegradable drug delivery compositions
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CN105764491A (en) 2013-12-09 2016-07-13 度瑞公司 Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CA3174824A1 (en) 2014-04-21 2015-10-29 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
EP3509601A1 (en) 2014-04-21 2019-07-17 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
US9730819B2 (en) 2014-08-15 2017-08-15 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9259339B1 (en) 2014-08-15 2016-02-16 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9855156B2 (en) 2014-08-15 2018-01-02 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9480588B2 (en) 2014-08-15 2016-11-01 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (en) 2015-06-03 2021-11-05 因塔西亚制药公司 Implant placement and removal system
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
ES2873887T3 (en) 2016-05-16 2021-11-04 Elixir Medical Corp Stent release
US11622872B2 (en) 2016-05-16 2023-04-11 Elixir Medical Corporation Uncaging stent
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
CN115666621A (en) 2020-01-13 2023-01-31 度勒科特公司 Sustained release drug delivery systems with reduced impurities and related methods

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6132420A (en) * 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
DE69734168T2 (en) 1996-02-02 2006-01-19 Alza Corp., Mountain View Implantable system with delayed release of active ingredient
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
ATE203157T1 (en) * 1996-12-20 2001-08-15 Alza Corp INJECTABLE DEPOSIT GEL PREPARATION AND PRODUCTION METHOD
ZA981610B (en) * 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
MY125849A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6368612B1 (en) 1997-12-12 2002-04-09 Biohybrid Technologies Llc Devices for cloaking transplanted cells
CA2315890C (en) * 1997-12-22 2009-08-11 Alza Corporation Rate controlling membranes for controlled drug delivery devices
JP4173635B2 (en) * 1997-12-29 2008-10-29 インターシア セラピューティクス，インコーポレイティド Permeation supply apparatus having membrane plug holding mechanism
EP1041974B1 (en) * 1997-12-30 2006-10-11 Alza Corporation Beneficial agent delivery system with membrane plug
WO2000029206A1 (en) 1998-11-13 2000-05-25 Sensor Technologies Inc. Monodisperse preparations useful with implanted devices
AU771132B2 (en) * 1998-12-31 2004-03-11 Intarcia Therapeutics, Inc. Osmotic delivery system having space efficient piston
US6703225B1 (en) * 1999-01-12 2004-03-09 Sumitomo Pharmaceuticals Company, Limited Interferon-α
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
EP1666026B2 (en) * 1999-02-08 2015-02-25 Intarcia Therapeutics, Inc Non-aqueous single phase biocompatible viscous vehicles and methods for preparing the same
US20030059376A1 (en) * 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
AU773354B2 (en) 1999-12-21 2004-05-20 Intarcia Therapeutics, Inc. Valve for osmotic devices
ATE309822T1 (en) * 2000-04-19 2005-12-15 Genentech Inc SUSTAINED RELEASE FORMULATIONS CONTAINING GROWTH HORMONE
BR0115392A (en) 2000-11-03 2004-06-15 Biomedicines Inc Method for the treatment of an interferon-sensitive disease in a warm-blooded animal, method for individualizing the dosages of an interferon in treatment, method for manufacturing a long-term therapeutic effect delivery device of a drug over a period of time, and useful set for delivering a relatively constant amount of a drug
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
KR20040019069A (en) 2001-07-20 2004-03-04 인터뮨, 인크. Methods of treating liver fibrosis
DE60239556D1 (en) 2001-11-14 2011-05-05 Durect Corp CATHETERINJICIBLE DEPOT COMPOSITIONS AND THEIR USE
BR0206984A (en) * 2001-11-14 2004-02-03 Alza Corp Injectable Depot Compositions and Use of These
CN100446809C (en) 2001-11-14 2008-12-31 阿尔扎有限公司 Injectable depot composition
AU2003221888B2 (en) * 2002-04-11 2008-11-06 Medimmune, Llc Preservation of bioactive materials by spray drying
MXPA04012976A (en) 2002-06-17 2005-05-16 Alza Corp Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle.
BR0312429A (en) 2002-06-26 2005-04-19 Alza Corp Minimal and volume efficient deformity piston for osmosis drug delivery systems
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
JP2006512370A (en) 2002-12-19 2006-04-13 アルザ・コーポレーション A stable non-aqueous single phase gel and its formulation for delivery from an implantable device
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN1767815A (en) 2003-03-31 2006-05-03 阿尔萨公司 Non-aqueous single phase vehicles and formulations utilizing such vehicles
KR20060017749A (en) 2003-03-31 2006-02-27 알자 코포레이션 Osmotic pump with means for dissipating internal pressure
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
JP2008528698A (en) 2005-02-03 2008-07-31 インターシア セラピューティクス，インコーポレイティド Implantable interferon-containing devices
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20060216242A1 (en) * 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
US7959938B2 (en) * 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
MX2008014870A (en) * 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846072B2 (en) 2004-09-17 2014-09-30 Durect Corporation Controlled delivery system
US8956644B2 (en) 2006-11-03 2015-02-17 Durect Corporation Transdermal delivery systems

Also Published As

Publication number Publication date
WO2006084141A2 (en) 2006-08-10
US20060251618A1 (en) 2006-11-09
CA2596966A1 (en) 2006-08-10
WO2006084139A3 (en) 2006-10-19
EP2361630A1 (en) 2011-08-31
JP2008528698A (en) 2008-07-31
WO2006084139A8 (en) 2007-12-27
WO2006084139A2 (en) 2006-08-10
US20060263433A1 (en) 2006-11-23
EP1877077A2 (en) 2008-01-16
WO2006084141A3 (en) 2006-09-21
US7655254B2 (en) 2010-02-02

Similar Documents

Publication Publication Date Title
WO2006084141A8 (en) Suspension formulation of interferon
WO2005115333A3 (en) A biomolecule-containing formulation of increased stability
WO2003080024A3 (en) Nanoparticulate compositions of map kinase inhibitors
WO2007075747A3 (en) Uv-radiation protectant compositions
WO2006034311A3 (en) Low voltage track and hold circuits
DK1443912T3 (en) Compositions with a combination of immediate and controlled release properties
EP1334712A3 (en) Compositions comprising at least one silicone, at least one compound comprising at least one ester group, and at least one copolymer, and methods for using the same
WO2007038220A3 (en) Organic-inorganic hybrid particle material and polymer compositions containing same
CA2326137A1 (en) Method for stabilizing pharmaceutical compositions by special use of an antioxidant
WO2006042132A3 (en) Microencapsulation of cells in hydrogels using electrostatic potentials
WO2006074462A3 (en) Electrostatic discharge protection for embedded components
WO2004071452A3 (en) Random and non-random alkylene oxide polymer alloy compositions
FI932123A0 (en) Stable, agglomerated water suspension in the form of an oil, polymer based on reducing friction
ATE457718T1 (en) STERILE FILTERED NANOPARTICLE FORMULATIONS OF BUDESONIDE WITH TYLOXAPOL AS SURFACE STABILIZER
TW200630422A (en) Stabilized orange materials containing fillers
TW200634181A (en) Electroplating composition and method
SG161203A1 (en) Nanoparticulate tacrolimus formulations
WO2008036423A3 (en) Formulations for voltage switchable dielectric material having a stepped voltage response and methods for making the same
WO2008080908A3 (en) Film forming composition comprising modified nanoparticles and modified nanoparticles for use in film forming compositions
WO2005009375A3 (en) Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
BRPI0518310A2 (en) transitory alumina particulate materials having controlled morphology and processing to form them
WO2007033372A3 (en) Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
WO2005111129A3 (en) Composition comprising polymer and derivatized nanoparticles
ATE418147T1 (en) CONDUCTIVE POLYMER COMPOSITIONS AND ARTICLES CONTAINING SAME
WO2004004683A8 (en) Solid dispersions comprising two different polymer matrixes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06720237

Country of ref document: EP

Kind code of ref document: A2